-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VZcnMrLxiNPR9zbO9tnCZnwz/AkhnaEWrYnPnTbbruyP4L3428NmiWrX19TY0fAB /YNw+CJjs73jfFGPGgOglg== 0001354457-10-000119.txt : 20100429 0001354457-10-000119.hdr.sgml : 20100429 20100429095555 ACCESSION NUMBER: 0001354457-10-000119 CONFORMED SUBMISSION TYPE: 25-NSE CONFIRMING COPY: PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20100429 DATE AS OF CHANGE: 20100429 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25-NSE SEC ACT: 1934 Act SEC FILE NUMBER: 000-24274 BUSINESS ADDRESS: STREET 1: 4365 EXECUTIVE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584526600 MAIL ADDRESS: STREET 1: 4365 EXECUTIVE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NASDAQ Stock Market LLC CENTRAL INDEX KEY: 0001354457 IRS NUMBER: 521165937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25-NSE BUSINESS ADDRESS: STREET 1: 9600 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-978-4144 MAIL ADDRESS: STREET 1: 9600 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 25-NSE 1 primary_doc.xml X0203 0001354457 NASDAQ Stock Market LLC 0000920465 LA JOLLA PHARMACEUTICAL CO 000-24274
6455 Nancy Ridge Drive San Diego CA CALIFORNIA 92121
858-452-6600 Common Stock 17 CFR 240.12d2-2(b) Amy Horton Associate General Counsel 2010-04-29 EX-99.25 2 ljpcdelistreason.txt Delisting Determination,The Nasdaq Stock Market, LLC, April 29, 2010, La Jolla Pharmaceutical Company. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the common stock of La Jolla Pharmaceutical Company (the Company), effective at the opening of the trading session on May 10, 2010. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rules 5110(a) and 5100. The Company was notified of the Staffs determination on January 19, 2010. The Company requested a review of that determation by the Hearings Panel. Upon review of the information provided by the Company, the Panel issed a decision dated March 2, 2010, which notified the Company that trading in the Companys securities would be suspended on March 4, 2010. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on April 16, 2010. -----END PRIVACY-ENHANCED MESSAGE-----